Answers are grounded in this paper and cite their sources.
Extracellular vesicles released by mesenchymal stromal cells (MSC-EVs) are increasingly viewed as candidates for cell-free neuroprotection, but their dose-response behavior in ischemic settings is poorly defined. Using rat hippocampal neuroglial cultures, we asked whether MSC-EVs can reproduce a hypoxia-like preconditioned state and how vesicle concentration shapes cell fate. EVs isolated from human placental MSCs by differential centrifugation were applied for 24 h at 2.4×108–2.4×109 particles/mL. Low-dose EVs (2.4×108) strengthened hypoxic preconditioning, attenuated OGD-induced global Ca2+ elevations, improved survival and metabolic activity, and shifted transcription toward anti-apoptotic (Bcl-2, Bcl-xL), neurotrophic (Gdnf), antioxidant (Sod1, Cat, HO-1), and pro-survival (Hif1α, Stat3) programs while lowering basal ROS. High-dose EVs (9.6×108 and above) reversed these effects: preconditioning was lost, Ca2+ oscillations became uncontrolled and progressed to overload, ROS rose, and pro-inflammatory (Tnfα, Il-1β) and pro-apoptotic (Caspase-3) genes were induced. Thus, MSC-EVs act within a narrow hormetic window, exerting protective effects at low doses and harmful effects at high doses; this constraint must inform therapeutic dosing.
No takes yet. Share an insight, caveat, or question.
Turovsky et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: